• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp (NQ: LEXX )

    2.210 -0.070 (-3.06%)
    Streaming Delayed Price Updated: 2:10 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lexaria Bioscience Corp

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024
    LEXX stock results show that Lexaria Bioscience missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024. 
    Via InvestorPlace
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
    Via ACCESSWIRE
    Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
    Via ACCESSWIRE
    Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
    Via ACCESSWIRE
    Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July
    Via Investor Brand Network
    Lexaria Awards Contract For Third GLP-1 Human Pilot Study
    Via ACCESSWIRE
    7 A-Rated Penny Stocks to Beat June Gloom
    Some penny stocks can be diamonds in the rough. These A-rated penny stocks are all solid picks for a portfolio this month. 
    Via InvestorPlace
    HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study
    Via Investor Brand Network
    7 A-Rated Biotech Stocks Worth Betting on in June
    A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
    Via InvestorPlace
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning! 
    Via InvestorPlace
    Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    7 A-Rated Penny Stocks Work Betting On in H2 2024
    For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits. 
    Via InvestorPlace
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024
    Via CannabisNewsWire
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024
    Via Investor Brand Network
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
    Via ACCESSWIRE
    CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Comprehensive GLP-1 Animal Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
    Via ACCESSWIRE
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.